{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:09Z","timestamp":1792270629130,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03655-8","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:03:41Z","timestamp":1781255021000},"page":"3810-3827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Joseph K.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Pfaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Desrosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0685-069X","authenticated-orcid":false,"given":"Jason","family":"Steenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Zuluaga","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"3","key":"3655_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/alr.22741","volume":"11","author":"RR Orlandi","year":"2021","unstructured":"Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213\u2013739.","journal-title":"Int Forum Allergy Rhinol"},{"key":"3655_CR2","volume-title":"Sino-nasal outcome test (SNOT-22)","author":"JF Piccirillo","year":"2006","unstructured":"Piccirillo JF. Sino-nasal outcome test (SNOT-22). St. Louis, Missouri: Washington University School of Medicine; 2006."},{"key":"3655_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1599797","volume":"6","author":"C Yang","year":"2025","unstructured":"Yang C, Guo L, Wang Y, Jiang W, Chen S, Gu Q. The advance on pathophysiological mechanisms of type\u00a02 chronic rhinosinusitis with nasal polyposis. Front Allergy. 2025;6:1599797.","journal-title":"Front Allergy"},{"issue":"1","key":"3655_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-016-0121-8","volume":"13","author":"SA Shah","year":"2016","unstructured":"Shah SA, Ishinaga H, Takeuchi K. Pathogenesis of eosinophilic chronic rhinosinusitis. J Inflamm Lond. 2016;13(1):11.","journal-title":"J Inflamm Lond"},{"issue":"6","key":"3655_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70070","volume":"15","author":"S Bogaert","year":"2025","unstructured":"Bogaert S, Rheindorf E, Dazert S, et al. Quality of life in type\u00a02 and non-type\u00a02 endotypes in chronic rhinosinusitis with nasal polyps: a prospective trial. Clin Transl Allergy. 2025;15(6):e70070.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"3655_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.anl.2023.08.002","volume":"51","author":"T Tsuda","year":"2024","unstructured":"Tsuda T, Suzuki M, Kato Y, et al. The current findings in eosinophilic chronic rhinosinusitis. Auris Nasus Larynx. 2024;51(1):51\u201360.","journal-title":"Auris Nasus Larynx"},{"issue":"12","key":"3655_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70117","volume":"15","author":"S Van Nevel","year":"2025","unstructured":"Van Nevel S, Zhang N, Xu Z, et al. Distinct effects of biological treatments on eosinophils and neutrophils in chronic rhinosinusitis with nasal polyp patients. Clin Transl Allergy. 2025;15(12):e70117.","journal-title":"Clin Transl Allergy"},{"key":"3655_CR8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/ohn.929","volume":"172","author":"JJ Shin","year":"2025","unstructured":"Shin JJ, Wilson M, McKenna M, et al. Clinical practice guideline: surgical management of chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2025;172:S1\u201347.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"3655_CR9","doi-asserted-by":"crossref","unstructured":"Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45\u201353.","DOI":"10.2147\/JAA.S86251"},{"key":"3655_CR10","doi-asserted-by":"crossref","unstructured":"Benson VS, Germain G, Chan RH, et al. Elucidating the real-world burden of chronic rhinosinusitis with nasal polyps in patients in the USA. OTO Open. 2022;6(4):2473974X221128930.","DOI":"10.1177\/2473974X221128930"},{"issue":"6","key":"3655_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12376","volume":"14","author":"T Mora","year":"2024","unstructured":"Mora T, S\u00e1nchez-Collado I, Mu\u00f1oz-Cano R, et al. Prevalence and coexistence of type\u00a02 inflammatory diseases. Clin Transl Allergy. 2024;14(6):e12376.","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"3655_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70032","volume":"15","author":"S Toppila-Salmi","year":"2025","unstructured":"Toppila-Salmi S, Lyly A, Simin J, Aakko J, Olsen HH, Lehtim\u00e4ki L. Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps. Clin Transl Allergy. 2025;15(2):e70032.","journal-title":"Clin Transl Allergy"},{"issue":"12","key":"3655_CR13","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1002\/lary.21446","volume":"121","author":"JA Stankiewicz","year":"2011","unstructured":"Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011;121(12):2684\u2013701.","journal-title":"Laryngoscope"},{"issue":"11","key":"3655_CR14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/alr.21377","volume":"4","author":"RM Leung","year":"2014","unstructured":"Leung RM, Dinnie K, Smith TL. When do the risks of repeated courses of corticosteroids exceed the risks of surgery? Int Forum Allergy Rhinol. 2014;4(11):871\u20136.","journal-title":"Int Forum Allergy Rhinol"},{"key":"3655_CR15","doi-asserted-by":"crossref","unstructured":"Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA. Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract. 2022;10(6):1434\u201353.e9.","DOI":"10.1016\/j.jaip.2022.03.002"},{"issue":"8","key":"3655_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100050","volume":"12","author":"L Ren","year":"2019","unstructured":"Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps\u2014state of the art. W Allergy Org J. 2019;12(8):100050.","journal-title":"W Allergy Org J"},{"key":"3655_CR17","doi-asserted-by":"crossref","unstructured":"Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C, Katotomichelakis M, editors. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy. International Forum of Allergy & Rhinology; 2024: Wiley Online Library.","DOI":"10.1002\/alr.23234"},{"issue":"10482","key":"3655_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase\u00a03, randomised, double-blind, parallel trials. Lancet. 2025;405(10482):911\u201326.","journal-title":"Lancet"},{"key":"3655_CR19","doi-asserted-by":"crossref","unstructured":"Peters AT, Han JK, Heffler E, et al. Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps. Clin Exp Immunol. 2025;219(1):uxaf041.","DOI":"10.1093\/cei\/uxaf041"},{"key":"3655_CR20","doi-asserted-by":"crossref","unstructured":"Han J, Lipworth B, Desrosiers M, et al. Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the phase\u00a03 WAYPOINT study. J Allergy Clin Immunol. 2025;155(2):AB442.","DOI":"10.1016\/j.jaci.2024.12.1018"},{"key":"3655_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol"},{"key":"3655_CR22","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. bmj. 2011;343:d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"3655_CR23","unstructured":"Chandler J, Cumpston M, Li T, Page MJ, Welch V. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley. 2019;4(1002):14651858."},{"key":"3655_CR24","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"2","key":"3655_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods"},{"issue":"4","key":"3655_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"issue":"4","key":"3655_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health"},{"issue":"1","key":"3655_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JP Jansen","year":"2013","unstructured":"Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1):159.","journal-title":"BMC Med"},{"issue":"11","key":"3655_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70114","volume":"15","author":"X Xu","year":"2025","unstructured":"Xu X, Lin J, Luo M, Wu Q. Which is the best biologic for nasal polyps: an updated network meta-analysis. Clin Trans Allergy. 2025;15(11):e70114.","journal-title":"Clin Trans Allergy"},{"issue":"10","key":"3655_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ph18101455","volume":"18","author":"A Safia","year":"2025","unstructured":"Safia A, Khater A, Abd Elhadi U, Merchavy S, Karam M. Optimizing biologic treatment selection in chronic rhinosinusitis with nasal polyps: a network meta-analysis of efficacy and safety across 22 RCTs. Pharmaceuticals. 2025;18(10):1455.","journal-title":"Pharmaceuticals"},{"key":"3655_CR31","volume-title":"NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014."},{"issue":"26","key":"3655_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"3655_CR33","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385.","journal-title":"N Engl J Med"},{"issue":"4","key":"3655_CR34","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","volume":"78","author":"P Gevaert","year":"2023","unstructured":"Gevaert P, De Craemer J, Bachert C, et al. European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis. Allergy. 2023;78(4):912\u201322.","journal-title":"Allergy"},{"issue":"10209","key":"3655_CR35","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, doubleblind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1 (Erratum in: Lancet. 2019 Nov 2;394(10209):1618. doi:\n10.1016\/S0140-6736(19)32218-4. PMID: 31543428).","journal-title":"Lancet."},{"issue":"5","key":"3655_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016;315(5):469\u201379. https:\/\/doi.org\/10.1001\/jama.2015.19330.","journal-title":"JAMA."},{"key":"3655_CR37","doi-asserted-by":"publisher","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7.","DOI":"10.1016\/S2213-2600(21)00097-7"},{"issue":"4","key":"3655_CR38","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME, Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol. 2017;140(4):1024\u201331.e14.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3655_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, De Ruyck N, Blomme K, Sousa AR, Marshall RP, Bachert C. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989\u201395.e1-8. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"3655_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605.","journal-title":"J Allergy Clin Immunol"},{"key":"3655_CR41","unstructured":"(2009) Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis. gov [www.clinicaltrials.gov]. 2009."},{"issue":"3","key":"3655_CR42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032 (Erratum in: J Allergy Clin Immunol. 2021 Jan;147(1):416. doi: 10.1016\/j.jaci.2020.11.003. PMID: 32524991).","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"3655_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000517976","volume":"30","author":"S Dhiman","year":"2021","unstructured":"Dhiman S, Dhiman A, Azad RK, Negi PC, Lal B, et al. Nasal polyposis and its association with cardiac functions. Med Principles Pract. 2021;30(6):522\u20136.","journal-title":"Med Principles Pract"},{"issue":"4","key":"3655_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2500\/ar.2016.7.0177","volume":"7","author":"S Sahin-Onder","year":"2016","unstructured":"Sahin-Onder S, Sahin-Yilmaz A, Oysu C, Deveci I, Sahin S, et al. Change in nasal congestion index after treatment in patients with chronic rhinosinusitis with nasal polyposis. Allergy Rhinol (Providence). 2016;7(4):193.","journal-title":"Allergy Rhinol (Providence)"},{"issue":"4","key":"3655_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(21)00457-4","volume":"10","author":"ES Lourijsen","year":"2022","unstructured":"Lourijsen ES, Reitsma S, Vleming M, Hannink G, Adriaensen GFJPM, et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. Lancet Respir Med. 2022;10(4):337\u201346.","journal-title":"Lancet Respir Med"},{"key":"3655_CR46","unstructured":"A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase\u00a03 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (WAYPOINT), Pub. L. No. D5242C00001(23 January 2025, 2025)."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03655-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:49Z","timestamp":1787385889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03655-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3655"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03655-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joseph K Han has received consultancy fees from AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals and Sanofi. Joaquim Mullol is or has been a member of national and international scientific advisory boards, consulted, received fees for lectures and grants for research projects or clinical trials from Almirall, AstraZeneca, Genentech-Roche, GSK, LETI, Lilly, Menarini, Mitsubishi-Tanabe, MSD, NOUCOR\/Uriach Group, Novartis, OptiNose, Proctor & Gamble, Regeneron Pharmaceuticals, Sanofi Genzyme, UCB Pharma and Viatris\/MEDA Pharmaceuticals. Claire Hopkins has participated in advisory boards for AstraZeneca, GSK, Lilly and Sanofi Genzyme. Oliver Pfaar reports grants and\/or personal fees and\/or travel support from AEDA, Alfried Krupp Krankenhaus, ALK-Abell\u00f3, Allergopharma, Almirall, Altamira Therapeutics, ASIT Biotech, AstraZeneca, Bencard Allergie GmbH\/Allergy Therapeutics, Biologixpharma, Blueprint, Breazy Health, Cliantha, Deutsche AllergieLiga e.V., Deutsche Forschungsgemeinschaft, Dustri-Verlag, ECM Expro&Conference Management GmBH, Forum f\u00fcr Medizinische Fortbildung, Georg-Thieme-Verlag, GSK, HAL Allergy Holding B.V.\/HAL Allergie GmbH, Inmunotek, Ingress Health, Institut f\u00fcr Disease Management, IQVIA Commercial, Japanese Society of Allergology, K\u00f6niglich D\u00e4nisches Generalkonsulat, Laboratorios LETI\/LETI Pharma, Lilly, Lofarma, Medizinische Hochschule Hannover, med update europe GmbH, Meinhardt Congress GmbH, Novartis, Paul-Ehrlich-Institut, Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter & Gamble, Red Maple Trials Inc., Regeneron, RG Aerztefortbildung, ROXALL Medizin, Sanofi Aventis, Sanofi Genzyme, Springer Publisher, Stallergenes Greer, streamedup! GmbH, Technical University Dresden, John Wiley & sons publishers, Wort & Bild Verlag, Verlag ME; all outside the submitted work, Oliver Pfaar is Vice President of the European Academy of Allergy and Clinical Immunology (EAACI), a member of EAACI Excom as well as a member of the external board of directors of the German Society of Allergy and Clinical Immunology (DGAKI); coordinator, main- or co-author of different position papers and guidelines in rhinology, allergology and allergen-immunotherapy; and he is Editor-in-Chief of\n                      Clinical Translational Allergy\n                      and Associate Editor of\n                      Allergy\n                      . Martin Desrosiers has received grants and speaker fees from AstraZeneca, GSK, Regeneron Pharmaceuticals and Sanofi; fees for consultancy from Boehringer Ingelheim and Insmed and is an equity holder with Probionase Therapies Inc. Jason Steenkamp is an employee of EVERSANA who received funding from AstraZeneca for conducting the statistical analyses that informed this study. Danny Gibson, Andrew Foster and Christopher Ambrose are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Santiago Zuluaga Sanchez is an employee of Amgen and owns stocks in Amgen.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based solely on previously published studies and does not include any new research involving human participants or animals conducted by the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}